BioSpace News Archive

Drug Development

Herantis Pharma Completes Patient Enrolment in Phase I Study of Lymfactin Gene Therapy for Secondary Lymphedema and Has Submitted Phase II Application

The company intends to proceed rapidly to a randomized, placebo-controlled Phase 2 study of Lymfactin in the same indication and has already submitted the clinical trial application to the regulatory authorities.

February 8, 2018

·

3 min read

Policy

Concept Life Sciences Expands GXP Compliance

Concept Life Sciences today announced the completion of the first phase of its GXP compliance plan, achieving GLP accreditation of its Dundee site for in vitro safety studies and bioanalysis.

February 8, 2018

·

1 min read

Business

Opiant Pharmaceuticals to Record Approximately $11.7M in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose

Opiant’s actual financial results for the five-month period ended December 31, 2017, will be reported in the Transition Report on Form 10-KT, to be filed in March 2018.

February 8, 2018

·

3 min read

Drug Development

Innovation Pharmaceuticals Concludes Successful Phase IIa Trial of Kevetrin for Ovarian Cancer; Intra-Tumor Modulation of p53 Observed

The Company initiated the trial for the purpose of demonstrating modulation of the key tumor-suppressor protein p53, which was achieved in analysis of the first patients at the lowest dose of Kevetrin.

February 8, 2018

·

7 min read

Business

Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018

The company will also host a webcast at 5:00 p.m. ET on Feb. 28, to discuss the results and 2018 guidance.

February 8, 2018

·

1 min read

Business

Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET

Genocea management will also provide an update on the Company’s recent progress and upcoming milestones.

February 8, 2018

·

1 min read

Business

Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin) for the Treatment of Hepatocellular Carcinoma

Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome technology and conduct certain pre-clinical and clinical activities through completion of a Phase IIa proof-of-concept clinical trial for the treatment of HCC.

February 8, 2018

·

9 min read

Business

Genedata Bioprocess Licensed to Pfizer

Improving data tracking and analysis via integrated data collection and enhanced data association can potentially help streamline data-focused development.

February 8, 2018

·

2 min read

Policy

Elite Pharmaceuticals and SunGen Pharma File ANDA

Under the terms of the Agreement, the product will be owned jointly by Elite and SunGen.

February 8, 2018

·

4 min read

Pharm Country

Neurotrope to Present at BIO CEO & Investor Conference

Neurotrope today announced that Daniel Alkon, MD, President and Chief Scientific Officer of Neurotrope, will present at the BIO CEO & Investor Conference to be held in New York City from February 12th-13th.

February 8, 2018

·

3 min read